Compare IDEXX Laboratories, Inc. (IDXX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Ryanair Holdings plc — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while Ryanair Holdings plc trades at $54.39 (market cap $27.11B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.66% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Ryanair Holdings plc for 72 Days on average.
| IDXX | RYAAY | |
|---|---|---|
Market Cap | $40.43B | $27.11B |
Volume | 692,164 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $766.68 | $73.82 |
52-Week Low | $504.70 | $51.95 |
Typical Hold Time | 46 Days | 72 Days |
Enterprise Value | $41.32B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
RYAAY trades at $53.05, down 5.27% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at 13.43 P/E. Recent earnings show mixed results with Q2 2026 missing expectations, while analysts maintain 64.71% buy rating. The company faces headwinds from fuel costs and Boeing MAX 10 certification delays, but maintains robust cash flow and balance sheet strength.
RYAAY presents a compelling value opportunity with solid profitability and growth prospects, though near-term volatility from oil prices and operational challenges warrants caution. The stock's current discount to historical valuations combined with strong market position supports long-term upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
